European working party on systemic lupus erythematosus and european forum on antiphospholipid antibodies: Two networks promoting European research on autoimmunity

Lupus

Volumn 18, Issue 10, 2009, Pages 863-868

  Cervera, Richard ^a   Tincani, A ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; HLA DQ ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; LA ANTIBODY; LUPUS ANTICOAGULANT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RO ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CLINICAL TRIAL; DISEASE EXACERBATION; EDITORIAL; EUROPE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL RESEARCH; MEDICAL SOCIETY; MORBIDITY; MORTALITY; PLEURISY; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VASCULITIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; COOPERATIVE BEHAVIOR; EUROPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 68949174054     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309106812     Document Type: Editorial

References (23)

1. Cervera R. European Working Party on Systemic Lupus Erythematosus: objectives and projects. Lupus 1992; 1(Suppl. 1): 29.
2. Cervera R Khamashta MA Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore) 1993; 72: 113-124.
3. Cervera R Khamashta MA Font J et al Morbidity and mortality in systemic lupus erythematosus. A multicenter prospective study of 1000 patients. Medicine (Baltimore) 1999; 78: 167-175.
4. Cervera R Khamashta MA Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. A comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 2003; 82: 299-308.
5. Galeazzi M Morozzi G Sebastiani GD et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. Clin Exp Rheumatol 1998; 16: 541-546.
6. Galeazzi M Bellisai F Sebastiani GD et al. Association of 16/6 and SA1 anti-DNA idiotypes with anticardiolipin antibodies and clinical manifestations in a large cohort of SLE patients. Clin Exp Rheumatol 1998; 16: 717-720.
7. Sebastiani GD Galeazzi M Tincani A et al. Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Scand J Rheumatol 1999; 28: 344-351.
8. Galeazzi M Annunziata P Sebastiani GD et al. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: Clinical, serological, and HLA class II gene associations. J Rheumatol 2000; 27: 135-141.
9. Galeazzi M Sebastiani GD Tincani A et al. HLA class II alleles associations of anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2000; 9: 47-55.
10. Galeazzi M Sebastiani GD Morozzi G et al. HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus. Correlations with clinical and autoantibody subsets. Medicine (Baltimore) 2002; 81: 169-178.
11. Sebastiani GD Galeazzi M Tincani A et al. HLA-DPB1 alleles association of anticardiolipin and anti-beta;2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2003; 12: 560-563.
12. Houssiau FA Vasconcelos C D'Cruz D et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
13. Houssiau FA Vasconcelos C D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940.
14. Tincani A Filippini M Scarsi M Galli M Meroni PL et al. European attempts for the standardization of the antiphospholipid antibodies. Lupus 2009; 18: 913-919.
15. Reber G Schousboe I Tincani A et al. Inter-laboratory variability of anti-β2-glycoprotein I measurement. Thromb Haemost 2002; 88: 66-73.
16. Sanmarco M Boffa M-C. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus 2009; 18: 920-923.
17. Tincani A Allegri F Balestrieri G et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-558.
18. Cervera R Boffa M-C Khamashta MA Hughes GRV. The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18: 889-893.
19. Cervera R; Khamashta MA; Shoenfeld Y; et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicenter prospective study of 1,000 patients. Ann Rheum Dis 2008 Sep 18. [Epub ahead of print]
20. Rotar Z Rozman B de Groot O et al. Sixth Meeting of the European Forum on Antiphospholipid Antibodies. How to improve the understanding of the antiphospholipid syndrome? Lupus 2009; 18: 53-60.
21. Bucciarelli S Espinosa G Cervera R. The CAPS Registry: Morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 2009; 18: 905-912.
22. Boffa M-C Lachassinne E Boinot C. European registry of babies born to mothers with antiphospholipid syndrome: A result update. Lupus 2009; 18: 900-904.
23. Avěin T Rozman B Cimaz R. The Ped-APS Registry: The antiphospholipid syndrome in childhood. Lupus 2009; 18: 894-899.